Mr. Todd Shapiro reports

RHELION LIFE SCIENCES' WHOLLY OWNED SUBSIDIARY FILAMENT HEALTH SHIPS PEX010 TO KING'S COLLEGE LONDON

Rhelion Life Sciences Corp. through its wholly owned subsidiary Filament Health Corp. has shipped PEX010 to King's College London for the feasibility study titled "Sleep Blinding Psilocybin: A feasibility study" (ISRCTN10648713), known as Sleepy.

Sleepy will evaluate a way of giving psilocybin just before sleep so that participants cannot tell whether they received it in healthy volunteers. The study is led by Dr. Raphael Rifkin-Zybutz at King's College London. King's College London and South London and Maudsley NHS Foundation Trust are the sponsors of the study. Filament is not the sponsor of the study and is not responsible for its conduct.

PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical-grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide. PEX010 is available in a standardized dosing range of one, five and 25 milligrams from a single drug candidate, with a 0.5-milligram dose to follow, produced using Filament's proprietary and patented extraction, purification and stabilization methods, giving investigators consistent composition across every dose, every study and every research site. On April 30, 2026, the company completed its previously announced acquisition of Filament Health, including its lead drug candidate, PEX010, and its portfolio of 78 issued patents across 13 patent families.

About Rhelion Life Sciences Corp.

Rhelion Life Sciences is a science- and research-led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health, the company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.

We seek Safe Harbor.